SELLAS Life Sciences Group, Inc. (SLS) Financials

SLS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 145.4 million 7.7 million
March 31, 2026 114.2 million 6.8 million
Dec. 31, 2025 78.3 million 7.5 million
Sept. 30, 2025 51.6 million 5.9 million

SLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -7.6 million 1.0 million
March 31, 2026 -8.8 million 798000
Dec. 31, 2025 -4.9 million 447000
Sept. 30, 2025 -7.1 million 503000

SLS Net Income

No data available :(

SLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 138.4 million 157000 -
March 31, 2026 107.2 million 309000 871000
Dec. 31, 2025 71.9 million 457000 1.0 million
Sept. 30, 2025 44.4 million - 599000

SLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 189.2 million
March 31, 2026 172.5 million
Dec. 31, 2025 153.1 million
Sept. 30, 2025 108.4 million

SLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 6.3 million 4.4 million -
March 31, 2026 - 5.1 million 4.1 million -
Dec. 31, 2025 - 4.7 million 3.5 million -
Sept. 30, 2025 - 4.2 million 2.9 million -

SLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - -
Dec. 31, 2025 - -
Sept. 30, 2025 - -

SLS

Price: $12.78

52 week price:
1.39
15.88

Earnings Per Share: -0.22 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 183300

Ebitda: -4.4 million

Market Capitalization: 2.5 billion

Links: